Jupiter Neurosciences, Inc. - JUNS Enterprise Value-to-Revenue Multiple

Jupiter Neurosciences Inc (JUNS) is developing an advanced platform to combat brain inflammation by overcoming neuronal barriers. The business outlook depends on the bioavailability of JNS101 and the efficacy of resveratrol in treating Alzheimer's disease. The Enterprise Value to revenue ratio visualizes the asset's market value, with the latest value recorded as 26000.00. Long-term drivers are linked to the publication of test data, while R&D risks are already priced in.
JUNS (jupiterneurosciences.com): analytical breakdowns and indicator data

For Jupiter Neurosciences Inc (JUNS), which utilizes outsourcing for production and marketing, the EV/Revenue ratio on the GURU.Markets platform reflects the market value of the business excluding debt load. This indicator compares the total enterprise value with sales volume, allowing investors to assess the efficiency of revenue capitalization and the resilience of assets to market shocks regardless of credit policy.